Oct 24th 2011 - Edison Investment Research today published a report on Aastrom Biosciences entitled "Leg-saving Cell Therapy". In summary, the report says:
Aastrom has developed a patient-specific cell therapy using a proprietary cell culture process. Its lead project in Critical Limb Ischaemia (CLI) aims to increase amputation-free survival in patients with blocked leg arteries. Strong Phase II data, to be fully reported 12-16 November, has led to a pivotal 594 patient Phase III starting Q411. A dilated heart indication has Phase II data with Phase IIb starting H112.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »